SuperworthRepligen profit margin RGEN
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- 5.3%
- Operating margin, 12 months
- 8.2%
- Net margin on a year earlier
- +7.3 pts
- Peer median
- 26.3%
Over the twelve months to Jun 30, 2026, Repligen kept 5.3% of its revenue as net profit, with an operating margin of 8.2% and a gross margin of 53.8%.
Five years earlier its net margin was 19.7%.
The median for 10 biotech stocks of a similar size is 26.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 6.6% | 7.5% | 52.7% |
| FY2024 | −4.0% | −5.5% | 43.3% |
| FY2023 | 5.6% | 7.5% | 44.0% |
| FY2022 | 23.2% | 28.0% | 56.9% |
| FY2021 | 19.1% | 24.9% | 58.3% |
| FY2020 | 16.4% | 19.1% | 57.2% |
| FY2019 | 7.9% | 13.4% | 55.9% |
| FY2018 | 8.6% | 13.4% | 55.4% |
| FY2017 | 20.1% | 9.9% | 52.5% |
| FY2016 | 11.2% | 15.3% | 54.9% |
| FY2015 | 11.2% | 16.5% | 57.8% |
| FY2014 | 12.9% | 16.8% | 55.9% |
| FY2013 | 23.6% | 33.6% | 63.1% |
| FY2012 | 22.7% | 17.8% | 56.4% |
| FY2011 | −12.4% | −10.9% | 71.9% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 5.3% | +7.3 pts | 8.2% | |
| Q1 FY26 | 6.7% | +10.3 pts | 8.5% | |
| Q4 FY25 | 6.6% | +10.6 pts | 7.5% | |
| Q3 FY25 | 0.2% | +1.5 pts | 0.1% | |
| Q2 FY25 | −2.1% | −3.6 pts | −3.5% | |
| Q1 FY25 | −3.5% | −7.3 pts | −5.0% | |
| Q4 FY24 | −4.0% | −9.7 pts | −5.5% | |
| Q3 FY24 | −1.3% | −16.7 pts | 1.8% | |
| Q2 FY24 | 1.5% | −15.9 pts | 3.8% | |
| Q1 FY24 | 3.8% | −16.5 pts | 6.1% | |
| Q4 FY23 | 5.6% | −17.6 pts | 7.5% | |
| Q3 FY23 | 15.4% | −5.3 pts | 13.3% |
Against its peers
Companies in Biotechnology nearest Repligen's size, closest first, today.
| Company | Profit margin |
|---|---|
| RGENRepligen | 5.3% |
| KRYSKrystal Biotech | 54.8% |
| TECHBIO-TECHNE | 15.0% |
| HALOHalozyme Therapeutics | 24.9% |
| NBIXNeurocrine Biosciences | 20.9% |
| EXELExelixis | 35.3% |
| INCYIncyte | 27.7% |
| UTHRUnited Therapeutics | 41.6% |
| ALNYAlnylam Pharmaceuticals | 16.8% |
| ADMAAdma Biologics | 33.0% |
| ONCBeOne Medicines | 10.7% |
| Peer median | 26.3% |
Where Repligen ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Repligen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.